Home » News » AIM News » Allergy Therapeutics plc Appoint Mary Tavener as Non-Executive Director
Allergy Therapeutics plc

Allergy Therapeutics plc Appoint Mary Tavener as Non-Executive Director

Allergy Therapeutics plc (LON: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, announced today that Mary Tavener will join the Board of Allergy Therapeutics as a Non-Executive Director with immediate effect. Mary will also join the Audit Committee of the Board and will work closely with the current chair Stephen Smith in anticipation of her succeeding Stephen as chair of the committee after the Group publishes its final results for the year ended 30 June 2019 in September.

Mary has extensive experience in the healthcare sector, having spent more than 19 years as Chief Financial Officer and Board member of AIM listed Advanced Medical Solutions. At AMS, Mary was responsible for strategy and risk management, finance, operations, regulatory, and legal. During her tenure through to the end of 2018, AMS delivered 15 consecutive years of growth, listed on AIM, and successfully conducted several transformational M&A deals. Mary is a Fellow of the Chartered Institute of Management Accountants (FCMA) and a Fellow of the Association of Corporate Treasurers (FCT). Prior to joining AMS, Mary was the Group Financial Controller of BTP plc.

Commenting on the appointment, Peter Jensen, Chairman of Allergy Therapeutics, said:

“I am delighted to announce Mary’s appointment and welcome her to the Board. Mary has an excellent track record and an impressive breadth of executive experience, and we look forward to the invaluable and trusted perspective she will bring to the Board.”

Commenting on her appointment, Mary Tavener said:

“Allergy Therapeutics has an excellent growth story since its formation as a small spinout from SmithKline Beecham in 1999. The business today has a broad range of assets in clinical development, a global presence across 23 markets, over 500 employees, and has achieved a 10% CAGR over the last 19 years as well as significant commercial success. I look forward to working with the Board to further develop Allergy’s leading position in the allergen immunotherapy sector.”